HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf608 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Michael G Miskelly und 19 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Cell Biology, Department of Experimental Medical Science, Lund University, Malmö 21428, Sweden. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Glucagon-Like Peptide 1, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Diabetes Wellness Research Foundation Sweden, Albert Påhlsson Foundation.
Abstract (Originalsprache)
Context
Statin use is associated with increased risk of type 2 diabetes (T2D) and mild hyperglycemia. The underlying mechanisms are not well studied, and the effect of statin treatment on glucagon-like peptide 1 (GLP-1) secretion or production is unknown.
Objective
This work aimed to assess the effects of rosuvastatin on GLP-1 secretion and production.
Methods
We performed association studies in the Malmö Diet and Cancer study cardiovascular cohort (MDCS-CC) reexamination cohort, in vitro investigations using GLUTag cells and acute and chronic studies in female, normoglycemic C57Bl/6j mice.
Results
Studies in the MDCS-CC reexamination cohort (n = 3734) revealed that in individuals without T2D, statin usage was associated with higher fasting glucose-dependent insulinotropic peptide (GIP), insulin, glucose, glucagon, and homeostatic model assessment of insulin resistance, but not GLP-1. However, in patients with T2D, statin usage was associated with higher fasting GLP-1 levels. Rosuvastatin treatment or 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (Hmgcr) knockdown (KD) reduced GLP-1 secretion and increased Gcg messenger RNA in GLUTag cells. Rosuvastatin acutely reduced postprandial GLP-1 secretion, whereas chronic rosuvastatin treatment in mice caused hyperglycemia and increased postprandial GLP-1 levels. The acute effect of Hmgcr KD on GLP-1 secretion could be mimicked by targeting intracellular cholesterol using a PCSK9 inhibitor. Finally, transcriptomic alterations induced by rosuvastatin were limited to genes involved in cholesterol biosynthesis.
Conclusion
We have established HMGCR as a regulator of GLP-1 secretion and provide a plausible explanation for the clinically observed mild hyperglycemia associated with statin use. Given the negative acute effect on GLP-1 secretion, monitoring of blood glucose levels is recommended after prescribing rosuvastatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroendocrine Cell Biology, Department of Experimental Medical Science, Lund University, Malmö 21428, Sweden.
- Department of Clinical Sciences, Lund University, Malmö 21428, Sweden.
- Unit of Molecular Metabolism, Lund University Diabetes Centre, Malmö 21428, Sweden.
- Islet Cell Exocytosis, Lund University Diabetes Centre, Lund University, Malmö 21428, Sweden.
- Diabetic Complications Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Malmö 21428, Sweden.
- Aleris Obesitas, Lund 22270, Sweden.
ORCID-Profile: Michael G Miskelly, Andreas Lindqvist, Amra Jujić, Alexander Hamilton, Elaine Cowan, Sweta Raikundalia, Rita Del Giudice, Dmytro Kryvokhyzha, Peter M Nilsson, Jens Juul Holst, Signe Sørensen Torekov, Jens O Lagerstedt, Maria F Gomez, Lena Eliasson, Hindrik Mulder, Jan Hedenbro, Martin Magnusson, Nils Wierup
Förderung
- Swedish Research Council
- Diabetes Wellness Research Foundation Sweden
- Albert Påhlsson Foundation
- Royal Physiographic Society in Lund
- Swedish Diabetes Foundation
- Lund University Diabetes Centre
- Swedish Foundation for Strategic Research
- grants from the Medical Faculty of Lund University Skane University Hospital
Zitieren
APA
Miskelly, M. G., Lindqvist, A., Jujić, A., Hamilton, A., Cowan, E., Raikundalia, S., Dutius Andersson, A. M., Nergård, B. J., Del Giudice, R., Kryvokhyzha, D., Nilsson, P. M., Holst, J. J., Torekov, S. S., Lagerstedt, J. O., Gomez, M. F., Eliasson, L., Mulder, H., Hedenbro, J., Magnusson, M., & Wierup, N. (2025). HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf608
Vancouver
Miskelly MG, Lindqvist A, Jujić A, Hamilton A, Cowan E, Raikundalia S, et al. HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf608
BibTeX
@article{Miskelly2025,
author = {Miskelly, Michael G and Lindqvist, Andreas and Jujić, Amra and Hamilton, Alexander and Cowan, Elaine and Raikundalia, Sweta and Dutius Andersson, Anna-Maria and Nergård, Bent J and Del Giudice, Rita and Kryvokhyzha, Dmytro and Nilsson, Peter M and Holst, Jens Juul and Torekov, Signe Sørensen and Lagerstedt, Jens O and Gomez, Maria F and Eliasson, Lena and Mulder, Hindrik and Hedenbro, Jan and Magnusson, Martin and Wierup, Nils},
title = {HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf608}
}
EUVIMED